MediWound (MDWD) VP reports stock options and RSU holdings in Form 3

Rhea-AI Filing Summary

MediWound Ltd. VP Clinical & Reg. Affairs Aya Ben Yaakov filed an initial Form 3 reporting existing equity holdings in the company. The filing lists several stock options to buy ordinary shares at exercise prices between 12.25 and 37.52 with expirations from 2028 to 2036, plus ordinary shares, including amounts underlying RSUs. Footnotes explain that these RSUs and options vest over four years, with 25% vesting after one year and 6.25% vesting quarterly thereafter. The filing shows holdings only, without any reported purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ben Yaakov Aya

(Last) (First) (Middle)

C/O MEDIWOUND LTD.

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Clinical & Reg. Affairs

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	432	D
Ordinary shares(1)	125	D
Ordinary shares(2)	1,800	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	12/31/2022	12/31/2028	Ordinary shares	1,571	$36.05	D
Stock Option (right to buy ordinary shares)	04/23/2024	04/23/2030	Ordinary shares	571	$12.25	D
Stock Option (right to buy ordinary shares)	03/04/2025	03/04/2031	Ordinary shares	357	$37.52	D
Stock Option (right to buy ordinary shares)	(3)	05/16/2032	Ordinary shares	2,142	$14.42	D
Stock Option (right to buy ordinary shares)	(4)	02/15/2033	Ordinary shares	2,800	$13.32	D
Stock Option (right to buy ordinary shares)	(5)	02/26/2034	Ordinary shares	3,298	$12.729	D
Stock Option (right to buy ordinary shares)	(6)	02/11/2035	Ordinary shares	2,500	$18.54	D
Stock Option (right to buy ordinary shares)	(7)	03/04/2036	Ordinary shares	15,000	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

3. The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

4. The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

5. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

6. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

7. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

	/s/ Yaron Meyer, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does MediWound (MDWD) VP Aya Ben Yaakov report in this Form 3?

Aya Ben Yaakov reports her initial equity holdings in MediWound, including stock options and ordinary shares. The filing details multiple option grants and RSU-based holdings, giving investors a snapshot of her compensation-linked stake at the time of becoming a reporting insider.

Are there any stock purchases or sales reported for MDWD in this Form 3?

No purchases or sales are reported; the Form 3 only lists existing holdings. It shows stock options and ordinary shares, including RSU-based amounts, as of the reporting date. This is a baseline ownership disclosure rather than a record of new trading activity in MediWound shares.

What stock options does the MediWound VP hold according to the Form 3?

The VP holds several stock options to buy MediWound ordinary shares, with exercise prices such as 36.0500, 12.2500, 37.5200, 14.4200, 13.3200, 12.7290, 18.5400, and 17.6000. These options expire between 2028 and 2036, reflecting multiple annual equity grants over recent years.

How do the MediWound RSUs granted to Aya Ben Yaakov vest?

Footnotes state the RSUs vest over four years: 25% vests on the first anniversary of the grant date, then 6.25% vests quarterly for three more years. This schedule applies to RSUs granted on February 15, 2023 and March 4, 2026, aligning vesting with multi-year service.

What is the vesting schedule for MediWound stock options held by the VP?

The options granted on May 16, 2022, February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026 vest over four years. For each grant, 25% vests after one year, then 6.25% vests quarterly over the next three years until fully vested.

Why is this MediWound Form 3 filing important for MDWD shareholders?

This Form 3 establishes the baseline equity stake of a key executive at MediWound. By detailing stock options and RSU-based ordinary shares, it shows how her compensation is tied to the company’s share performance, helping shareholders understand management’s long-term alignment with the business.